Soleno Therapeutics Inc (SLNO) - Total Liabilities
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has total liabilities worth $112.59 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Soleno Therapeutics Inc to track the company's year-over-year net asset growth rate.
Soleno Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See SLNO cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Soleno Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Soleno Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AIMA Technology Group Co Ltd
SHG:603529
|
China | CN¥14.61 Billion |
|
Jiangsu Sidike New Materials Sci Te
SHE:300806
|
China | CN¥5.43 Billion |
|
Four Corners Property Trust Inc
NYSE:FCPT
|
USA | $1.29 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
USA | $4.69 Billion |
|
Easy Click Worldwide Network Technology Co. Ltd. A
SHE:301171
|
China | CN¥3.08 Billion |
|
Doximity Inc
NYSE:DOCS
|
USA | $172.85 Million |
|
Kaynes Technology India Limited
NSE:KAYNES
|
India | Rs20.49 Billion |
|
Steadfast Group Limited
F:1S6
|
Germany | €3.80 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Soleno Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Soleno Therapeutics Inc (SLNO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soleno Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $113.72 Million | +32.44% |
| 2024-12-31 | $85.86 Million | +270.34% |
| 2023-12-31 | $23.18 Million | +43.56% |
| 2022-12-31 | $16.15 Million | -9.07% |
| 2021-12-31 | $17.76 Million | -8.62% |
| 2020-12-31 | $19.43 Million | -16.32% |
| 2019-12-31 | $23.23 Million | +82.33% |
| 2018-12-31 | $12.74 Million | +2.01% |
| 2017-12-31 | $12.49 Million | +486.33% |
| 2016-12-31 | $2.13 Million | -57.21% |
| 2015-12-31 | $4.98 Million | -73.42% |
| 2014-12-31 | $18.73 Million | -52.53% |
| 2013-12-31 | $39.45 Million | +7.47% |
| 2012-12-31 | $36.71 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more